Drug interactions between Equetro and Risperdal
| Results for the following 2 drugs: |
|---|
| Equetro (carbamazepine) |
| Risperdal (risperidone) |
Interactions between your selected drugs
carbamazepine ↔ risperidone
Applies to:Equetro (carbamazepine) and Risperdal (risperidone)
MONITOR: Coadministration with carbamazepine may decrease the plasma concentrations of risperidone and its pharmacologically active metabolite, 9-hydroxyrisperidone. The proposed mechanism is carbamazepine induction of CYP450 3A4-mediated metabolism. In 11 patients comedicated with carbamazepine, the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone were lower compared to those of 23 patients who were treated with risperidone alone, although the difference was statistically significant only for the metabolite. In a subgroup of five patients who were assessed with and without carbamazepine comedication, dose-normalized plasma risperidone and 9-hydroxyrisperidone concentrations were significantly lower for combination therapy than for risperidone alone. In a case report, the interaction was suspected in two patients treated with the drugs who developed parkinsonian symptoms several weeks following the discontinuation of carbamazepine. The symptoms resolved completely in both cases within a week after risperidone dosage was reduced.
MANAGEMENT: Patients treated concomitantly with carbamazepine may require a higher dosage of risperidone to control psychotic symptoms. Pharmacologic response and plasma risperidone levels should be monitored more closely whenever carbamazepine is added to or withdrawn from therapy in patients stabilized on their existing antipsychotic regimen, and the risperidone dosage adjusted as necessary.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
